Rank Categories 2012 Total (Billions) (Billions)

\$25.9

\$24.0

Fig. 3: Top 20 Therapeutic Classes by US Sales '12

Oncologics

3	Respiratory Agents	\$22.1	\$21.7	
4	Antidiabetics	\$22.0	\$20.5	
5	Pain	\$18.2	\$17.9	
6	Lipid Regulators	\$16.9	\$21.3	
7	Autoimmune Diseases	\$14.8	\$12.5	
8	Antihypertensives	\$13.6	\$14.0	
9	HIV Antivirals	\$11.7	\$10.4	
10	ADHD	\$10.4	\$9.2	
11	Anti-Ulcerants	\$10.0	\$10.5	
12	Multiple Sclerosis	\$8.9	\$7.6	
13	Antibacterials	\$7.9	\$9.3	
14	Nervous System Disorders	\$7.2	\$6.9	
15	Vaccines	\$6.8	\$6.4	
16	Hormonal Contraception	\$5.5	\$5.2	
17	Other CNS	\$5.0	\$4.8	
18	Immunostimulants	\$4.7	\$4.6	
19	Antivirals, excl. Anti-HIV	\$4.5	\$3.8	
20	Platelet Aggregation Inhibitors	\$4.4	\$8.2	
	Total others Total market	\$82.0 \$325.8	\$80.9 \$329.2	

*On January 2, 2013, Abbott's research-based pharma business, AbbVie, became a separate entity